Literature DB >> 22994905

Analysis of longitudinal clinical trials with missing data using multiple imputation in conjunction with robust regression.

Devan V Mehrotra1, Xiaoming Li, Jiajun Liu, Kaifeng Lu.   

Abstract

In a typical randomized clinical trial, a continuous variable of interest (e.g., bone density) is measured at baseline and fixed postbaseline time points. The resulting longitudinal data, often incomplete due to dropouts and other reasons, are commonly analyzed using parametric likelihood-based methods that assume multivariate normality of the response vector. If the normality assumption is deemed untenable, then semiparametric methods such as (weighted) generalized estimating equations are considered. We propose an alternate approach in which the missing data problem is tackled using multiple imputation, and each imputed dataset is analyzed using robust regression (M-estimation; Huber, 1973, Annals of Statistics 1, 799-821.) to protect against potential non-normality/outliers in the original or imputed dataset. The robust analysis results from each imputed dataset are combined for overall estimation and inference using either the simple Rubin (1987, Multiple Imputation for Nonresponse in Surveys, New York: Wiley) method, or the more complex but potentially more accurate Robins and Wang (2000, Biometrika 87, 113-124.) method. We use simulations to show that our proposed approach performs at least as well as the standard methods under normality, but is notably better under both elliptically symmetric and asymmetric non-normal distributions. A clinical trial example is used for illustration.
© 2012, The International Biometric Society No Claim to original US government works.

Mesh:

Year:  2012        PMID: 22994905     DOI: 10.1111/j.1541-0420.2012.01780.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  Recovery Support for Adolescents with Substance use Disorders: The Impact of Recovery Support Telephone Calls Provided by Pre-Professional Volunteers.

Authors:  Bryan R Garner; Mark D Godley; Lora L Passetti; Rodney R Funk; William L White
Journal:  J Subst Abus Alcohol       Date:  2014-04

2.  Robust estimation of models for longitudinal data with dropouts and outliers.

Authors:  Yuexia Zhang; Guoyou Qin; Zhongyi Zhu; Bo Fu
Journal:  J Appl Stat       Date:  2020-11-10       Impact factor: 1.416

3.  Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.

Authors:  John J P Kastelein; Jennifer G Robinson; Michel Farnier; Michel Krempf; Gisle Langslet; Christelle Lorenzato; Daniel A Gipe; Marie T Baccara-Dinet
Journal:  Cardiovasc Drugs Ther       Date:  2014-06       Impact factor: 3.727

4.  Comparison of intent-to-treat analysis strategies for pre-post studies with loss to follow-up.

Authors:  Wenna Xi; Michael L Pennell; Rebecca R Andridge; Electra D Paskett
Journal:  Contemp Clin Trials Commun       Date:  2018-05-09

5.  Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.

Authors:  Henry N Ginsberg; Daniel J Rader; Frederick J Raal; John R Guyton; Marie T Baccara-Dinet; Christelle Lorenzato; Robert Pordy; Erik Stroes
Journal:  Cardiovasc Drugs Ther       Date:  2016-10       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.